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Introduction: Methyldopa and labetalol are the drugs that frequently used for the management of pregnancy‑induced 
hypertension. But fewer data available for the efficacy and safety of their use. So, here we are doing a systemic review for 
the safety and efficacy of methyldopa in comparison to labetalol.
Objectives: Assessment of efficacy and safety of methyldopa versus labetalol in pregnancy‑induced hypertension.
Method: A total of 10 randomized controlled trials (RCTs) following PRISMA guidelines (2015) and have included pregnant 
women who developed hypertension after the 20th week of gestation and receiving methyldopa (100–400 mg/day) or 
labetalol (250–1000 mg/day). All RCTs with changes in mean arterial pressure (MAP) before and after drug administration 
was collected. The adverse effects of the respective drugs were also noted. RevMan 5.3 software was used for the calculation 
of standardized mean difference (SMD). P value less than 0.05 will be considered significant.
Result: Data of 1,200 patients were included in our study. Both the drug decreases MAP statistically significantly. In the 
labetalol group, P value was statistically significant (random effect model P < 0.005 and in the fixed‑effect model <0.001). 
In methyldopa group, P < 0.001, significant in fixed effect. In the majority of the studies, the difference in the reduction 
of MAP was higher in labetalol than methyldopa. In labetalol vs methyldopa study using random‑effect model SMD was 
1.568 (95% CI, 0.735 to 2.401, P < 0.001). Drowsiness, headache, nausea, vomiting, weakness, and myalgia were associated 
with drugs. Out of the six adverse effects, there was a significant difference found in drowsiness (P = 0.023) which was seen 
more in patients receiving methyldopa. There was no significant difference in the prevalence of the other maternal side effects.
Conclusions: Labetalol is more efficacious and safer as compared to methyldopa.
Key words: Efficacy; labetalol; methyldopa; pregnancy‑induced hypertension; safety.
Introduction
Hypertensive disorders are the most common medical 
complications of pregnancy, affecting 7.8% of all pregnancies in 
India and account for approximately a quarter of all antenatal 
admissions.[1] These disorders are responsible for approximately 
one-third of maternal mortality in India.[2] Despite years of 
research in this field, there remains a lack of consensus on the 
classification/definition of hypertensive disorders of pregnancy, 
the blood pressure at which antihypertensive therapy needs to 
be initiated, what constitutes an appropriate antihypertensive 
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agent in pregnancy and the maternal-fetal-risk-benefit 
ratio of treatment.[3] There is evidence that hospitalization 
early in the course of the disease improves maternal and 
perinatal outcomes, but the use of antihypertensive drugs 
in pregnancy-induced hypertension (PIH) is currently under 
debate.[4,5] This meta-analysis is used to determine and compare 
the efficacy of treatment with methyldopa vs labetalol with 
respect to maternal-perinatal benefits and adverse effects.
PIH is the development of new hypertension in a pregnant 
woman after 20 weeks of gestation along with having 
blood pressure greater than 140/90 on two separate 
occasions at least 6 h apart and without the presence of 
protein in the urine.[6,7] If not treated it leads to a condition 
known as pre-eclampsia, which is defined as gestational 
hypertension + proteinuria.[8] In later stages, if tonic-clonic 
seizures develop along with the above two preexisting 
conditions, it aggravates to eclampsia.[9] Eclampsia is serious 
for both mother and baby which can cause a coma in the 
mother and can be fatal for both.[10] Thus, it is the doctor’s 
utmost priority to treat PIH in its earlier stages.
An array of anti-hypertensive drugs is available out of which 
methyldopa is the oldest drug giving promising results in 
treating PIH while Labetalol is a rather unique drug that 
has shown to be effective in the treatment of essential 
hypertension while its uses in treating PIH are still being 
assessed.[11]
Methyldopa is a phenylalanine derivative and an aromatic 
amino acid decarboxylase inhibitor its anti-hypertensive 
actions seems to be attributable to its conversion into 
alpha-methyl norepinephrine, which is a potent alpha-2 
adrenergic agonist that binds to and stimulates potent 
central inhibitory alpha-2 adrenergic receptors. This results 
in a decrease in sympathetic outflow and decreased blood 
pressure.[12]
Labetalol is a third-generation selective alpha-1-adrenergic 
antagonist and nonselective beta-adrenergic antagonist. It 
competitively binds to alpha-1-adrenergic receptors in vascular 
smooth muscle, thereby inhibiting the adrenergic stimulation 
of endothelial cell function and vasoconstriction in peripheral 
blood vessels. This agent also binds to beta-receptors in the 
bronchial and vascular smooth muscle, resulting in a decrease 
in both systolic and diastolic blood pressure.[13]
Methods
This is a meta-analysis between two different drugs used 
in PIH.
Step 1: Identification and literature search
We identified original randomized controlled trials by an 
all-language search of all articles (any year up to May 2019) 
in the Cochrane Controlled Trials Register (CCTR), Medline, 
Google Scholar, and EMBASE. We subsequently screened 
the references of all retrieved articles to identify additional 
relevant publications. The following search strings and MESH 
terms were used: “Methyldopa vs Labetalol” OR “Gestational 
Hypertension treatment AND randomized controlled trial.”
Step 2: Criteria for selection of studies




•	 Studies	 that	 were	 double‑blind,	 single‑blind,	 or	
unblinded,
•	 Studies	that	included	a	comparison	of	methyldopa	with	
labetalol individuals with PIH.
We included any RCT in pregnant women with gestational 
hypertension that compared the effects of methyldopa and 
labetalol on blood pressure and their respective adverse effects.
All RCTs which followed CONSORT (1996) and PRISMA (2015) 
guidelines were included.
Step 3: RCT enrolment criteria
Inclusion criteria
•	 All	the	pregnant	women	were	normotensive	before	the	






We took care not to include any study population more than 
once if it featured in more than one publication.
Step 4: Type of intervention
Methyldopa vs labetalol in PIH.
Step 5: Clinical outcome measure
Primary Outcome:
Significant decrease in mean arterial pressure (MAP) after 
treatment with methyldopa and labetalol.
Secondary Outcome:
Adverse effects assessment between methyldopa and 
labetalol.
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Step 6: Data extraction
We extracted systolic blood pressure (SBP) and diastolic 
blood pressure (DBP) or the MAP depending on their 
availability before and after treatment in individual RCTs of 
the primigravid pregnant women. MAP = (2DBP + SBP)/3. The 
prevalence of individual adverse effects of the respective drugs 
was also extracted. Data were extracted into a data extraction 
form using standard QUOROM (2000) reporting guidelines. 
Data were verified by two independent researchers, and any 
discrepancies were resolved by consensus.
Data were extracted for the prevalence of adverse effects 
caused by the active drugs from the included RCTs. They 
were later compared.
Step 7: Nullification of bias
Authors assured to include studies in which allocation 
of control and experimental groups were adequately 
randomized and there was no conflict of interest as well as 
match to inclusion and exclusion criteria.
Step 8: Measures of treatment effect
A direct comparison between methyldopa and labetalol was 
done using a fixed and random effect model and standardized 
mean deviation (SMD) was calculated. Data from publications 
comparing the two antihypertensive monotherapies with 
each other was used to calculate the difference in the before 
and after treatment MAP of each drug for the individual 
RCTs. These differences were taken into account to perform 
a meta-analysis and generate the SMD for individual RCTs.
Step 9: Summary measures
A fixed and random effect model test was used for a direct 
comparison between active drugs. The principal summary 
measure was done with a 95% confidence interval with SMDs 
and funnel as well as a forest plot. RevMan®Version 5.38 
was used for analysis. The I2 test was used to measure the 
heterogeneity. A paired t-test was performed to find if 
there was a significant difference in the number of adverse 
effects between the drugs. A P value of less than 0.05 was 
considered significant.
Results
As shown in Figure 1, a total of 58 published papers were 
identified and 48 of those were rejected for various reasons. 
As per Table 1, two were review articles rather than original 
research, 33 were not randomized clinical trials, and 13 
were published as abstracts. The remaining 10 studies 
including 1,200 primigravid pregnant women suffering from 
PIH were included in the meta-analysis. These remaining 
studies compared methyldopa and labetalol on their effect 
in reducing the blood pressure in these women and their 
respective adverse effects.
Data for clinical evaluation for comparing the efficacy was 
available in all the 10 studies. In some studies, the blood 
pressure was given in the form of systolic blood pressure (SBP) 
and diastolic blood pressure (DBP) while in some in the form 
of MAP. To standardize the analysis and make the work more 
convenient, the only MAP was extracted from all the studies 
using the formula (2DBP + SBP)/3 = MAP in those required.
610 pregnant women were given labetalol of dose 
250–1000 mg/day. Table 2 shows the MAP (mmHg) before and 
Figure 1: Preferred reporting items for systematic reviews and meta‑analyses 
flow diagram
Table 1: Studies included in the meta-analysis
Sr. No Study ID Sample size Methyldopa Labetalol Type of study References
1 Bidisha Roychoudhury (2015) 400 200 200 Drug Comparison, RCT 14
2 Vaidehi Subhedar (2013) 180 90 90 Drug Comparison, RCT 15
3 G.D.Lamming (1979) 19 9 10 Drug Comparison, RCT 16
4 Mary Rohini Pentareddy (2017) 60 30 30 Drug Comparison, RCT 17
5 Nidhi Maheshwari (2016) 60 30 30 Drug Comparison, RCT 18
6 Reena Verma (2012) 90 45 45 Drug Comparison, RCT 19
7 Kavita Babbar (2015) 108 56 52 Drug Comparison, RCT 20
8 Afzal Qasim (2014) 120 60 60 Drug Comparison, RCT 21
9 Archana Bharti (2016) 78 39 39 Drug Comparison, RCT 22
10 Shaba N. Molvi (2012) 85 51 24 Drug Comparison, RCT 23
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after treatment with labetalol (n1) for individual researches. 
590 pregnant women were given methyldopa of dose 
100–400 mg/day. Table 3 shows the MAP (mmHg) before and 
after treatment with Methyldopa (n2) for individual researches.
Both of the drugs show a decrease in the MAP (mmHg) after 
their consumption. Figure 2 compares the efficacy of these 
drugs. Here, the differences in the MAP before and after the 
treatment for both the drugs in individual studies are plotted. 
These differences were taken into account to perform a 
meta-analysis and SMDs were generated. During the statistical 
procedure, labetalol was considered n1 while methyldopa n2. 
A forest plot [Figures 3 and 4] is plotted to display these.
In a majority of the studies (n = 8) the difference in the 
reduction of MAP was higher in labetalol than methyldopa. 
Figure 2: Comparing the efficacy of active drug
Table 2: Effect of labetalol
Sr No. of study No of cases (nl) MAP Before RX (mmHg) MAP After Rx (mmHg) P value
Bidisha Roychoudhury (2015) 200 115.29±4.39 107.7±2.59 <0.001
Vaidehi Subhedar (2013) 90 109.49±2.78 96.9±2.7 <0.05
G.D.Lamming (1979) 10 112.9±4.9 91.7±7.1 <0.001
Mary Rohini Pentareddy (2003) 30 112.337±6.6 93.22±5.23 <0.001
Nidhi Maheshwari (2016) 30 111.28±5.28 101.36±6.932 <0.001
Reena Verma (2012) 45 117.74±8.63 93.03±7.08 <0.05
Kavita Babbar (2015) 52 109.56±4.3 96.4±5.1 <0.05
Afzal Qasim (2014) 60 116.67±8.33 93.67±7.66 <0.05
Archana Bharti (2016) 39 131.47±8.1 113.07±8.067 <0.01
Shaba. N.Molvi (2012) 34 114±4.5 94.33±6 <0.0001
Total 610 115.0737 (Mean) 98.138 (Mean) <0.001
Table 3: Effect of methyldopa
Sr No. of study No. of cases(n2) MAP Before RX (mmHg) MAP After Rx (mmHg) P value
Bidisha Roychoudhury (2015) 200 120.5±6.37 113.39±3.32 <0.001
Vaidehi Subhedar (2013) 90 109.86±2.91 98.15±3.44 <0.05
G.D.Lamming (1979) 9 110±6.7 100.8±11.9 <0.01
Mary Rohini Pentareddy (2003) 30 110.443±6.06 95.553±4.58 <0.001
Nidhi Maheshwari (2016) 30 109.91±5.68 99.93±9.35 <0.001
Reena Verma (2012) 45 118.51±7.53 94.36±8.04 <0.05
Kavita Babbar(2015) 56 109.72±5.5 98.2±5.3 <0.05
Afzal Qasim (2014) 60 117.33±8.66 96.33±7.33 <0.05
Archana Bharti (2016) 39 132.53±8.367 122.97±11.033 <0.01
Shaba. N.Molvi (2012) 51 115±3 94.3±6 <0.0001
Total 590 115.3803 (Mean) 101.3983 (Mean) <0.001
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Lamming (1979) (SMD is +2.931) and Bharti (2016) (SMD 
is +2.321)[16] showed the highest difference [Table 4].[22] 
While	in	one	study	Maheshwari	(2016)	(SMD	is	−0.02)	the	
drugs were found to be equally efficacious.[18] But, in only 
one	study	Shaba.	Molvi	(2012)	(SMD	is	−0.394)	the	efficacy	
of methyldopa was found better than labetalol [Table 4].
Figure 5 shows the prevalence of adverse effects for 
each drug in eight studies except Maheshwari (2016) and 
Lamming (1979). Paired and unpaired t-tests were performed 
to show if there was a significant difference in the number 
of adverse effects caused between the drugs. Out of the six 
adverse effects, there was a significant difference found in 
drowsiness (P = 0.023) which was seen more in Methyldopa 
complemented patients.
Discussion
The primary objective of management in women with PIH 
is to protect the safety of the mother and the fetus and 
the subsequent delivery of a healthy baby. It is crucial to 
remember that up to a quarter of patients with PIH may 
progress to preeclampsia, with nearly 10% of the patients 
progressing to develop eclampsia.[24-26] Furthermore, 
as was shown in a recent case series of patients with 
preeclampsia,[27] pregnant women who develop hemorrhagic 
stroke in the setting of hypertension generally have BP 
well below the traditional levels of severe hypertension. 
In this context, the demonstration in the present study 
that early antihypertensive treatment of PIH reduces both 
the progression of hypertension and the development of 
proteinuria is clinically important.
As stated, methyldopa is the oldest drug giving promising 
results while labetalol is rather a unique drug and its 
efficacy in treating PIH were still unknown. In the present 
Figure 3: Forest plot
Figure 4: Funnel plot with SE
Table 4: SMDs with 95% CI
Study SMD 95% Cl
Bidisha Roychoudhury (2015) 0.191 ‑0.00536 to 0.388
Vaidehi Subhedar (2013) 2.312 1.933 to 2.691
G.D.Lamming (1979) 2.931 1.566 to 4.297
Mary Rohini Pentareddy (2003) 0.898 0.326 to 1.469
Nidhi Maheshwari (2016) ‑0.0208 ‑0.531 to 0.489
Reena Verma (2012) 0.481 0.0597 to 0.903
Kavita Babbar (2015) 3.257 2.676 to 3.837
Afzal Qasim (2014) 1.887 1.454 to 2.320
Archana Bharti (2016) 4.635 3.772 to 5.499
Shaba.N.Molvi (2012) ‑0.394 ‑0.835 to 0.0462
Total (fixed effects) 0.86 0.733 to 0.987
Total (random effects) 1.568 0.735 to 2.401
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study, antihypertensive medication was associated with 
a significantly reduced incidence of composite maternal 
endpoint, even after adjustment for other predictors of 
adverse maternal outcomes. These findings suggest that 
routine antihypertensive therapy for PIH may offer protection 
against some non-fatal maternal adverse events. Hence, it can 
be inferred that the starting of antihypertensives in pregnant 
women with gestational hypertension produces a significant 
reduction in blood pressure.
According to this meta-analysis majority of the studies showed 
labetalol to be efficacious and even quicker than its competitor 
in treating PIH. Roychoudhary (2015),[14] Subhedar (2015),[15]
Lamming (1979),[16] Pentareddy (2013),[17] Verma (2012),[19] 
Babbar (2015),[20] Qasim (2014),[21] and Bharti (2015)[22] these 
all studies showed significantly higher (P < 0.05) efficacy 
of labetalol.[20-22] 51% of the primigravids were given labetalol 
and 49% of the primigravids were given methyldopa.[14-23]
Drowsiness, headache, nausea, vomiting, weakness, and 
myalgia are the six adverse effects that are caused by both 
drugs. Of all the side effects, methyldopa regularly causes 
drowsiness and its tendency to cause it is significantly more 
than labetalol with P = 0.023. There was no significant 
difference in the prevalence of the other maternal side 
effects by the drugs as their P value after doing paired and 
unpaired t-test was more than 0.05. Headache (P = 0.252), 
n a u s e a  ( P  =  0 . 8 0 3 ) ,  v o m i t i n g  ( P  =  0 . 7 5 6 ) , 
weakness (P = 0.396), myalgia (P = 0.818). Drowsiness is 
particularly disturbing to individuals doing mental work and 
represents the overall most important side effect. Methyldopa 
being a more central drug may be a cause for it.
Although this analysis has limited studies (n = 10), as a 
majority of the studies show Labetalol to be significantly 
superior, a robust assessment of publication bias was 
achievable.
Conclusion
This analysis showed that labetalol is more advantageous 
than methyldopa in terms of better and quicker control of 
blood pressure. Labetalol has comparatively fewer maternal 
side-effects with the good prenatal outcomes. Thus, Labetalol 
having less maternal side effects is a smarter choice for 
treating PIH for better outcomes.
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